Vir BiotechnologyVIR
VIR
About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Employees: 408
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
141% more call options, than puts
Call options by funds: $9.81M | Put options by funds: $4.07M
50% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 28
6% more funds holding
Funds holding: 196 [Q3] → 208 (+12) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 69
0.43% less ownership
Funds ownership: 64.91% [Q3] → 64.47% (-0.43%) [Q4]
2% less capital invested
Capital invested by funds: $664M [Q3] → $652M (-$12.3M) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
100%
upside
Avg. target
$36
410%
upside
High target
$110
1,471%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Barclays Gena Wang 17% 1-year accuracy 5 / 30 met price target | 343%upside $31 | Overweight Maintained | 28 Feb 2025 |
HC Wainwright & Co. Patrick Trucchio 23% 1-year accuracy 42 / 182 met price target | 1,471%upside $110 | Buy Reiterated | 28 Feb 2025 |
Needham Joseph Stringer 15% 1-year accuracy 18 / 122 met price target | 171%upside $19 | Buy Reiterated | 27 Feb 2025 |
Leerink Partners Roanna Ruiz 22% 1-year accuracy 2 / 9 met price target | 186%upside $20 | Outperform Maintained | 13 Jan 2025 |
Morgan Stanley Michelle Gilson 0% 1-year accuracy 0 / 1 met price target | 186%upside $20 | Overweight Upgraded | 9 Jan 2025 |
Financial journalist opinion
Based on 6 articles about VIR published over the past 30 days
Neutral
Business Wire
21 hours ago
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for sub.
Neutral
Seeking Alpha
2 weeks ago
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Hang Hu - Barclays Paul Choi - Goldman Sachs Phil Nadeau - TD Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham Patrick Trucchio - H.C. Wainwright & Co. Operator Hello.
Negative
Zacks Investment Research
2 weeks ago
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.86 per share a year ago.
Neutral
Business Wire
2 weeks ago
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2024. “2024 was a year of transformation for Vir Biotechnology as we successfully defined and executed on our renewed strategic direction, focusing our resources on our most promising programs in infectious diseases and oncology,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Bio.
Neutral
Business Wire
3 weeks ago
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotech.
Neutral
Business Wire
4 weeks ago
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025. The corporate update and financial results will be provided via a press release after market close and will be accessible on the News page in the Investors s.
Positive
Seeking Alpha
1 month ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Positive
Benzinga
2 months ago
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
On Wednesday, Vir Biotechnology, Inc. VIR presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC).
Positive
Zacks Investment Research
2 months ago
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
Positive
Seeking Alpha
2 months ago
Vir Biotechnology: A Rocket Off Phase 1 Data
Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation.
Charts implemented using Lightweight Charts™